Early response to Saxenda results in improvement in weight loss
Three-year data presented at the European Obesity Summit (EOS 2016) show early response to Novo Nordisk’s Saxenda (liraglutide 3 mg) resulted in improvements in weight loss and cardiometabolic risk factors.
Click on this link for more information.
